What is the Carfilzomib?

Carfilzomib is , while it's Molecular Formula is C 40 H 57 N 5 O 7 . Carfilzomib is a second-generation proteasome inhibitor that is used as a treatment in relapsed and refractory multiple myeloma.

What is the CAS number for Carfilzomib?

The CAS number of Carfilzomib is 868540-17-4.

What is Carfilzomib (868540-17-4) used for?

In July 2012, the US FDA approved carfilzomib (also referred to as PR-171) for the treatment of patients with multiple myeloma (MM) who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression within 60 days of completion of the last therapy. Carfilzomib binds to and irreversibly inhibits the chymotrypsin-like protease activity of the constitutive proteosome (β5) and immunoproteosome (β5i) via its epoxyketone pharmacophore. Proteosome inhibition results in the accumulation of polyubiquitinated proteins and induction of apoptosis through activation of both the intrinsic and extrinsic caspase pathways. Carfilzomib inhibits chymotrypsin activity with an IC50 of 6 nM and is less potent an inhibitor of trypsin and caspase (IC50s of 3600 and 2400 nM, respectively). Cell cycle arrest and apoptosis are seen in a variety of hematologic and solid tumor cell lines (e.g.,MM, acutemyeloid leukemia (AML), pancreatic cancer, lung cancer) treated with carfilzomib. The synthesis of carfilzomib is reported in the patent literature and a route to the intermediate epoxy ketone from a Boc-leucine-derived α,β-unsaturated ketone is also described.InChI:InChI=1/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1

What is the Carfilzomib?

Carfilzomib is , while it's Molecular Formula is C 40 H 57 N 5 O 7 . Carfilzomib is a second-generation proteasome inhibitor that is used as a treatment in relapsed and refractory multiple myeloma.

What is the CAS number for Carfilzomib?

The CAS number of Carfilzomib is 868540-17-4.

What is Carfilzomib (868540-17-4) used for?

In July 2012, the US FDA approved carfilzomib (also referred to as PR-171) for the treatment of patients with multiple myeloma (MM) who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression within 60 days of completion of the last therapy. Carfilzomib binds to and irreversibly inhibits the chymotrypsin-like protease activity of the constitutive proteosome (β5) and immunoproteosome (β5i) via its epoxyketone pharmacophore. Proteosome inhibition results in the accumulation of polyubiquitinated proteins and induction of apoptosis through activation of both the intrinsic and extrinsic caspase pathways. Carfilzomib inhibits chymotrypsin activity with an IC50 of 6 nM and is less potent an inhibitor of trypsin and caspase (IC50s of 3600 and 2400 nM, respectively). Cell cycle arrest and apoptosis are seen in a variety of hematologic and solid tumor cell lines (e.g.,MM, acutemyeloid leukemia (AML), pancreatic cancer, lung cancer) treated with carfilzomib. The synthesis of carfilzomib is reported in the patent literature and a route to the intermediate epoxy ketone from a Boc-leucine-derived α,β-unsaturated ketone is also described.InChI:InChI=1/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1

Product Class

868540-17-4

Product Name：Carfilzomib
Molecular Formula：C₄₀H₅₇N₅O₇
Purity：99%
Molecular Weight：719.922

Inquiry

Product Details:

CasNo： 868540-17-4

Molecular Formula： C₄₀H₅₇N₅O₇

Buy Quality Carfilzomib,Export 868540-17-4 Cheap Price

Molecular Formula:C₄₀H₅₇N₅O₇
Molecular Weight:719.922
Vapor Pressure:0mmHg at 25°C
Refractive Index:1.551
Boiling Point:975.627 °C at 760 mmHg
PKA:13.17±0.46(Predicted)
Flash Point:543.84 °C
PSA：158.47000
Density:1.162g/cm³
LogP:4.08500

Carfilzomib(Cas 868540-17-4) Usage

description	Carfilzomib is a targeted cancer drug classified as a proteasome inhibitor. It is used in the treatment of refractory multiple myeloma, a type of bone marrow cancer that has not responded to previous therapies.
Side effects	The most common adverse events observed in clinical trials (incidence ≥30%) were fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea and fever; the most common serious adverse events (overall incidence 45%) include pneumonia, acute renal failure, fever and congestive heart failure.
Chemical Properties	White Solid
Originator	Proteolix Inc. (United States)
Uses	Carfilzomib has been approved for the treatment of multiple myeloma in patients who have not responded to previous therapies. It is used alone to treat relapsed or refractory multiple myeloma in patients who have received one or more previous treatments. Clinical studies have demonstrated the efficacy of carfilzomib in various cancers, including multiple myeloma, lymphoma, and solid tumors. It inhibits chymotrypsin activity and induces cell cycle arrest and apoptosis in hematologic and solid tumor cell lines.
Definition	ChEBI: A synthetic tetrapeptide consisting of morpholin-4-acetyl, L-2-amino-4-phenylbutanoyl, L-leucyl and L-phenylalanyl residues joined in sequence with the C-terminus connected to the amino group of (2
Brand name	Kyprolis
Drug interactions	Potentially hazardous interactions with other drugs Antipsychotics: avoid with clozapine - increased risk of agranulocytosis.
Metabolism	Carfilzomib was rapidly and extensively metabolised by mainly peptidase cleavage and epoxide hydrolysis. Cytochrome P450 mediated mechanisms played a minor role in overall carfilzomib metabolism. The metabolites have no known biologic activity.

InChI:InChI=1/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1

868540-17-4 Relevant articles

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

List of authors. A. Keith Stewart, M.B., Ch.B., S. Vincent Rajkumar, M.D., Meletios A. Dimopoulos, M.D., Tamás Masszi, M.D., Ph.D., Ivan Špička, M.D., Ph.D., Albert Oriol, M.D., Roman Hájek, M.D., Ph.D., Laura Rosiñol, M.D., Ph.D., David S. Siegel, M.D., Ph.D., Georgi G. Mihaylov, M.D., Ph.D., Vesselina Goranova-Marinova, M.D., Ph.D., Péter Rajnics, M.D., Ph.D.

N Engl J Med 2015; 372:142-152

We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival.

U.S. Food and Drug Administration Approval: Carfilzomib for the Treatment of Multiple Myeloma

Thomas M. Herndon; Albert Deisseroth; Edvardas Kaminskas; Robert C. Kane; Kallappa M. Koti; Mark D. Rothmann; Bahru Habtemariam; Julie Bullock; Jeffrey D. Bray; Jessica Hawes; Todd R. Palmby; Josephine Jee; William Adams; Houda Mahayni; Janice Brown; Angelica Dorantes; Rajeshwari Sridhara; Ann T. Farrell; Richard Pazdur

Clin Cancer Res (2013) 19 (17): 4559–4563.

The safety of carfilzomib was evaluated in 526 patients with multiple myeloma treated with various dosing regimens. The ORR was 23%. The median duration of response was 7.8 months. The most common adverse reactions associated with carfilzomib infusion were fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and fever.

868540-17-4 Process route

: 247068-81-1
tert-butyl [(1S)-3-methyl-1-(2-methylpropyl)-2-oxobut-3-en-1-yl]carbamate

: 868540-17-4
carfilzomib

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1: calcium hypochlorite / water; 1-methyl-pyrrolidin-2-one / 0.33 h / -15 - 0 °C 2: dichloromethane / 2 h / 0 - 20 °C / Inert atmosphere 3: benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate / N,N-dimethyl-formamide / 1.5 h / 0 - 5 °C With calcium hypochlorite; benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In 1-methyl-pyrrolidin-2-one; dichloromethane; water; N,N-dimethyl-formamide;
Multi-step reaction with 3 steps 1: sodium hypochlorite; pyridine / water / 2 h / -5 - 0 °C 2: dichloromethane / 2 h / 0 - 20 °C / Inert atmosphere 3: benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate / N,N-dimethyl-formamide / 1.5 h / 0 - 5 °C With pyridine; sodium hypochlorite; benzotriazol-1-ol; O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In dichloromethane; water; N,N-dimethyl-formamide;
Multi-step reaction with 3 steps 1: potassium carbonate; benzonitrile; dihydrogen peroxide / methanol / 6 h / 25 - 30 °C 2: trifluoroacetic acid / dichloromethane / 3 h / 5 - 10 °C / Inert atmosphere 3: dichloromethane / 1 h With dihydrogen peroxide; potassium carbonate; benzonitrile; trifluoroacetic acid; In methanol; dichloromethane;
Multi-step reaction with 3 steps 1: potassium carbonate; benzonitrile; dihydrogen peroxide / methanol / 6 h / 25 - 30 °C 2: trifluoroacetic acid / dichloromethane / 3 h / 5 - 10 °C / Inert atmosphere 3: dichloromethane / 3 h / 25 - 30 °C With dihydrogen peroxide; potassium carbonate; benzonitrile; trifluoroacetic acid; In methanol; dichloromethane;
Multi-step reaction with 5 steps 1: cerium(III) chloride heptahydrate; sodium tetrahydroborate / methanol / 1 h / 0 - 5 °C 2: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 0 - 30 °C 3: Dess-Martin periodane / acetonitrile / 3 h / 0 - 30 °C 4: dichloromethane / 2 h / 2 - 30 °C 5: benzotriazol-1-ol; benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / acetonitrile / 0 - 5 °C / Inert atmosphere With sodium tetrahydroborate; cerium(III) chloride heptahydrate; benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; benzotriazol-1-ol; Dess-Martin periodane; N-ethyl-N,N-diisopropylamine; 3-chloro-benzenecarboperoxoic acid; In methanol; dichloromethane; acetonitrile;
Multi-step reaction with 6 steps 1.1: cerium(III) chloride heptahydrate; sodium tetrahydroborate / methanol / 1 h / 0 - 5 °C 2.1: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 0 - 30 °C 3.1: Dess-Martin periodane / acetonitrile / 3 h / 0 - 30 °C 4.1: dichloromethane / 2 h / 2 - 30 °C 5.1: benzotriazol-1-ol; benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / acetonitrile / -10 - -5 °C 5.2: 0.5 h / 25 - 30 °C 6.1: sodium hydrogencarbonate / dichloromethane; water / 0.17 h / 2 - 6 °C With sodium tetrahydroborate; cerium(III) chloride heptahydrate; benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; sodium hydrogencarbonate; benzotriazol-1-ol; Dess-Martin periodane; N-ethyl-N,N-diisopropylamine; 3-chloro-benzenecarboperoxoic acid; In methanol; dichloromethane; water; acetonitrile;
Multi-step reaction with 8 steps 1.1: cerium(III) chloride heptahydrate; sodium tetrahydroborate / methanol / 1 h / 0 - 5 °C 2.1: 3-chloro-benzenecarboperoxoic acid / dichloromethane / 0 - 30 °C 3.1: Dess-Martin periodane / acetonitrile / 3 h / 0 - 30 °C 4.1: dichloromethane / 2 h / 2 - 30 °C 5.1: benzotriazol-1-ol; benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 2 - 6 °C 6.1: trifluoroacetic acid / dichloromethane / 2 - 6 °C 7.1: benzotriazol-1-ol; benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine / N,N-dimethyl-formamide / 2 - 6 °C 7.2: 0.5 h / 25 - 30 °C 8.1: sodium hydrogencarbonate / dichloromethane; water / 0.17 h / 2 - 6 °C With sodium tetrahydroborate; cerium(III) chloride heptahydrate; benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; sodium hydrogencarbonate; benzotriazol-1-ol; Dess-Martin periodane; N-ethyl-N,N-diisopropylamine; 3-chloro-benzenecarboperoxoic acid; trifluoroacetic acid; In methanol; dichloromethane; water; N,N-dimethyl-formamide; acetonitrile;

: 868540-16-3
(S)-2-((S)-4-methyl-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamido)-3-phenyipropanoic acid

: C₉H₁₇NO₂*C₃HF₅O₂

: 868540-17-4
carfilzomib